Virax Biolabs Group (VRAX) Competitors

$0.28 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.29 +0.01 (+3.78%)

As of 05/22/2026 07:59 PM Eastern

VRAX vs. APM, BGMS, INM, RVPH, and MBIO

Should you buy Virax Biolabs Group stock or one of its competitors? MarketBeat compares Virax Biolabs Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virax Biolabs Group include Aptorum Group (APM), Cyclacel Pharmaceuticals (BGMS), InMed Pharmaceuticals (INM), Reviva Pharmaceuticals (RVPH), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry.

How does Virax Biolabs Group compare to Aptorum Group?

Virax Biolabs Group (NASDAQ:VRAX) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Aptorum Group has higher revenue and earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	120.44	-$6.06M	N/A	N/A
Aptorum Group	$430K	12.55	-$1.36M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Aptorum Group	N/A	N/A	N/A

Virax Biolabs Group currently has a consensus target price of $1.00, suggesting a potential upside of 260.36%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe Virax Biolabs Group is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Virax Biolabs Group has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Aptorum Group. Virax Biolabs Group's average media sentiment score of 1.24 beat Aptorum Group's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
Aptorum Group	Neutral

Summary

Virax Biolabs Group beats Aptorum Group on 8 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Cyclacel Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Cyclacel Pharmaceuticals has higher revenue and earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.14	-$3M	-$4.54	N/A
Virax Biolabs Group	$10K	120.44	-$6.06M	N/A	N/A

In the previous week, Virax Biolabs Group had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Cyclacel Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 1.24 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Neutral
Virax Biolabs Group	Positive

Virax Biolabs Group has a consensus target price of $1.00, indicating a potential upside of 260.36%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Virax Biolabs Group	N/A	N/A	N/A

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Virax Biolabs Group beats Cyclacel Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Virax Biolabs Group compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Virax Biolabs Group has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Virax Biolabs Group's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has lower revenue, but higher earnings than InMed Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.15	-$8.16M	-$2.89	N/A
Virax Biolabs Group	$10K	120.44	-$6.06M	N/A	N/A

InMed Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Virax Biolabs Group has a consensus price target of $1.00, indicating a potential upside of 260.36%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, InMed Pharmaceuticals had 24 more articles in the media than Virax Biolabs Group. MarketBeat recorded 25 mentions for InMed Pharmaceuticals and 1 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 1.24 beat InMed Pharmaceuticals' score of 0.32 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Virax Biolabs Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Virax Biolabs Group beats InMed Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to Reviva Pharmaceuticals?

Virax Biolabs Group (NASDAQ:VRAX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Virax Biolabs Group presently has a consensus target price of $1.00, indicating a potential upside of 260.36%. Reviva Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 16,042.05%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Virax Biolabs Group has higher revenue and earnings than Reviva Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	120.44	-$6.06M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of 1.24 beat Reviva Pharmaceuticals' score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virax Biolabs Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Virax Biolabs Group has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Virax Biolabs Group's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

Virax Biolabs Group beats Reviva Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Mustang Bio?

Virax Biolabs Group (NASDAQ:VRAX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Virax Biolabs Group's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Mustang Bio	N/A	-35.38%	-16.36%

Mustang Bio has lower revenue, but higher earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	120.44	-$6.06M	N/A	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

In the previous week, Virax Biolabs Group had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Mustang Bio. Virax Biolabs Group's average media sentiment score of 1.24 beat Mustang Bio's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
Mustang Bio	Neutral

Virax Biolabs Group has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Virax Biolabs Group presently has a consensus target price of $1.00, suggesting a potential upside of 260.36%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Virax Biolabs Group beats Mustang Bio on 9 of the 12 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.20M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.74	21.00	25.66
Price / Sales	120.44	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.22	7.09	10.41	7.14
Net Income	-$6.06M	$24.45M	$3.57B	$335.98M
7 Day Performance	-10.19%	6.38%	6.40%	4.11%
1 Month Performance	75.63%	2.43%	3.54%	2.52%
1 Year Performance	-72.79%	62.98%	34.14%	35.04%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	3.2893 of 5 stars	$0.28 flat	$1.00 +260.4%	-72.8%	$1.20M	$10K	N/A	5	Positive News Gap Up
APM Aptorum Group	0.5427 of 5 stars	$0.81 -3.5%	N/A	-4.3%	$5.33M	$430K	N/A	30	Gap Up
BGMS Cyclacel Pharmaceuticals	1.0029 of 5 stars	$0.96 +0.4%	N/A	N/A	$5.30M	$750K	N/A	14	Gap Down
INM InMed Pharmaceuticals	1.791 of 5 stars	$1.61 +0.6%	N/A	-37.7%	$5.30M	$4.94M	N/A	10	Gap Down
RVPH Reviva Pharmaceuticals	2.2757 of 5 stars	$0.39 -3.5%	$66.67 +16,945.9%	-98.0%	$5.01M	N/A	N/A	5	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. APM, BGMS, INM, RVPH, and MBIO

How does Virax Biolabs Group compare to Aptorum Group?

Summary

How does Virax Biolabs Group compare to Cyclacel Pharmaceuticals?

Summary

How does Virax Biolabs Group compare to InMed Pharmaceuticals?

Summary

How does Virax Biolabs Group compare to Reviva Pharmaceuticals?

Summary

How does Virax Biolabs Group compare to Mustang Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. APM, BGMS, INM, RVPH, and MBIO

How does Virax Biolabs Group compare to Aptorum Group?

Which has preferable valuation & earnings, VRAX or APM?

Is VRAX or APM more profitable?

Do analysts rate VRAX or APM?

Do institutionals & insiders hold more shares of VRAX or APM?

Which has more volatility & risk, VRAX or APM?

Does the media favor VRAX or APM?

Summary

How does Virax Biolabs Group compare to Cyclacel Pharmaceuticals?

Which has more risk and volatility, BGMS or VRAX?

Which has higher valuation and earnings, BGMS or VRAX?

Does the media prefer BGMS or VRAX?

Do analysts rate BGMS or VRAX?

Is BGMS or VRAX more profitable?

Do insiders & institutionals hold more shares of BGMS or VRAX?

Summary

How does Virax Biolabs Group compare to InMed Pharmaceuticals?

Is INM or VRAX more profitable?

Which has preferable earnings & valuation, INM or VRAX?

Which has more volatility and risk, INM or VRAX?

Do analysts rate INM or VRAX?

Do insiders and institutionals believe in INM or VRAX?

Does the media prefer INM or VRAX?

Summary

How does Virax Biolabs Group compare to Reviva Pharmaceuticals?

Do analysts prefer VRAX or RVPH?

Do institutionals & insiders believe in VRAX or RVPH?

Which has better earnings & valuation, VRAX or RVPH?

Does the media favor VRAX or RVPH?

Which has more risk and volatility, VRAX or RVPH?

Is VRAX or RVPH more profitable?

Summary

How does Virax Biolabs Group compare to Mustang Bio?

Is VRAX or MBIO more profitable?

Which has higher valuation & earnings, VRAX or MBIO?

Does the media favor VRAX or MBIO?

Which has more volatility and risk, VRAX or MBIO?

Do insiders and institutionals have more ownership in VRAX or MBIO?

Do analysts recommend VRAX or MBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools